Kimia Biosciences Share Price | Kimia Biosciences Stock Screener
KIMIABL
Pharmaceuticals
Share Price BSE
₹36.50
▼
-0.30 (-0.82%)
As of May 21, 2026, the Kimia Biosciences share price (BSE: KIMIABL) is ₹36.50, down 0.82% from the previous close, with shares trading between ₹35.80 and ₹36.85, and a 52-week range of ₹23.55–₹80.78.
Check KIMIABL 52-week performance for the annual price range and momentum.
Use the Kimia Biosciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Kimia Biosciences Market Cap
₹168.68 Cr.
KIMIABL P/E Ratio (TTM)
19.30
Kimia Biosciences P/B Ratio
15.06
EPS (TTM)
₹2.03
Dividend Yield
-
Debt to Equity
7.46
KIMIABL 52 Week High
₹80.78
Kimia Biosciences 52 Week Low
₹23.55
Operating Margin
15.00%
Profit Margin
7.09%
KIMIABL Revenue (TTM)
₹127.00
EBITDA
₹21.00
Net Income
₹9.00
Total Assets
₹111.00
Total Equity
₹10.00
Kimia Biosciences Share Price Chart
Screen Kimia Biosciences share price with an interactive chart. Analyse KIMIABL price trends and volatility across different timeframes.
Kimia Biosciences Company Profile - Fundamental Screener
Screen Kimia Biosciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for KIMIABL shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE285U01025
Kimia Biosciences Balance Sheet Screener
Screen KIMIABL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 111 | 100 | 121 | 110 | 107 | 86 | 65 | 58 | 12 | 4 |
| Current Assets | 75 | 61 | 83 | 73 | 72 | 61 | 48 | 43 | 2 | 1 |
| Fixed Assets | 33 | 32 | 34 | 35 | 28 | 18 | 16 | 13 | 7 | 3 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 19 | 30 | 40 | 33 | 37 | 34 | 29 | 25 | 9 | 7 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 10 | 0 | 6 | 15 | 18 | 13 | 6 | 2 | -5 | -4 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 2 | 2 | 7 | 7 |
| Reserves & Surplus | 5 | -4 | 1 | 10 | 14 | 9 | 2 | -2 | -12 | -11 |
Kimia Biosciences Income Statement Screener - Profit & Revenue Analysis
Screen Kimia Biosciences income statement and profit fundamentals.
Analyze KIMIABL quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Kimia Biosciences share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127 | 120 | 107 | 130 | 126 | 135 | 107 | 95 | 77 | 2 | 0 | 2 |
| Expenses | 106 | 99 | 105 | 134 | 124 | 124 | 102 | 88 | 74 | 2 | 4 | 4 |
| EBITDA | 21 | 22 | 1 | -4 | 2 | 11 | 5 | 7 | 3 | 0 | -3 | -1 |
| Operating Profit % | 15.00% | 17.00% | 0.00% | -4.00% | 1.00% | 6.00% | 4.00% | 6.00% | 3.00% | -67.00% | -1759.00% | -110.00% |
| Depreciation | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 0 |
| Interest | 4 | 5 | 5 | 4 | 4 | 3 | 3 | 2 | 1 | 0 | 1 | 0 |
| Profit Before Tax | 13 | 14 | -7 | -12 | -5 | 6 | 1 | 4 | 2 | -1 | -4 | -2 |
| Tax | 0 | 4 | -2 | -3 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 9 | 10 | -5 | -9 | -4 | 5 | 1 | 4 | 2 | -1 | -4 | -2 |
| EPS | 1.90 | 2.03 | -1.12 | -1.98 | -0.78 | 1.08 | 0.33 | 2.64 | 1.14 | -1.26 | -5.49 | -2.31 |
Kimia Biosciences Cash Flow Screener - Liquidity Fundamentals
Screen KIMIABL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 21 | 15 | -7 | 8 | 6 | 0 | -3 | -7 | -1 | -6 |
| Investing Activities | -5 | -2 | -3 | -1 | -14 | -9 | -2 | -2 | -6 | 0 |
| Financing Activities | -17 | -13 | 10 | -8 | 8 | 9 | 4 | 10 | 7 | 6 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 0 | 0 |
Kimia Biosciences Shareholding Pattern Screener
See Kimia Biosciences shareholding pattern with promoter, FII, and DII holdings.
Check Kimia Biosciences promoter holding and ownership changes for KIMIABL on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 22.88% | 23.04% | 23.04% | 22.93% | 22.92% | 23.05% | 23.05% | 23.03% |
| Other Holding | 1.80% | 1.64% | 1.64% | 1.75% | 1.75% | 1.63% | 1.63% | 1.65% |
| Shareholder Count | 12,775 | 12,278 | 12,200 | 12,616 | 12,751 | 12,110 | 12,023 | 12,179 |
Kimia Biosciences Share Dividend Screener - Share Yield Analysis
Check Kimia Biosciences dividend history with payout and yield data.
View Kimia Biosciences dividend details including ex-dates and amounts for KIMIABL stock.
Kimia Biosciences Stock Index Membership
See which indices include Kimia Biosciences stock.
Check KIMIABL index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Kimia Biosciences Market Events Screener - Corporate Actions
Get Kimia Biosciences corporate actions including splits, bonuses, and buybacks.
Check Kimia Biosciences stock events that may affect KIMIABL share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -1.53% | ||
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | 25.71% |
| 2025-12-30 | 2025-12-30 | Annual General Meeting | NA | -9.62% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 0.25% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -7.15% |
| 2025-07-22 | 2025-07-22 | Extraordinary General Meeting | NA | 39.79% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 3.95% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -8.06% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -3.78% |
| 2019-01-04 | 2019-01-04 | Change Of Name | NA | 0.00% |
Kimia Biosciences Competitors Screener - Peer Comparison
Screen KIMIABL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Kimia Biosciences Company Announcements - News Screener
Screen KIMIABL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-27 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-18 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-14 | Clarification On Price Movement In The Scrip Of The Company - BSE Email Dated April 13 2026 Bearing Reference No. L/SURV/ONL/PV/APJ/2026-2027/3695- Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-04-13 | Clarification sought from Kimia Biosciences Ltd | - |
| 2026-04-04 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-03 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-03-23 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-18 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-02-16 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Modification In Postal Ballot Notice | - |
| 2026-02-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-14 | Financials Results For The Quarter And Nine Months Ended 31 December 2025 | - |
| 2026-02-14 | Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI(Listing Obligations And Disclosures Requirement) Regulation 2015 | - |
| 2026-02-10 | Non-Applicability Of Opening Of Suspense Escrow Account In Connection With Municipal Bond | - |
| 2026-02-10 | Intimation Under Regulation 30 Of SEBI(Listing Obligations And Disclosure Requirements) Regulations2015 -Granted A Patent For Improved Process For The Preparation Of Luliconazole For 20 Years | - |
| 2026-02-07 | Board Meeting Intimation for Board Meeting Intimation For Consider And Approve The Un-Audited (Standalone) Financial Results For The Quarter And Nine Months Ended On 31St December 2025 | - |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) | - |